Pancreatic Cancer Research

ResearcherUniversity of RochesterActive in the last 2 years

Richard Francis Dunne

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6608-660X; OpenAlex author ID A5016395449. Sources: OpenAlex.

Their work

Papers
16
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 3 papers · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers

Papers 16

  1. The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review. Co-author DOI 10.1002/jcsm.13510↗
  2. SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical study. Co-author DOI 10.1016/j.humpath.2024.01.013↗
  3. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  4. The Interplay Among Pancreatic Cancer, Cachexia, Body Composition, and Diabetes. Co-author DOI 10.1016/j.hoc.2022.07.001↗
  5. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  6. Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot. Co-author DOI 10.1200/jco.21.02616↗
  7. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  8. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cell.2020.03.062↗
  9. Incidence and Significance of GATA3 Positivity in Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma. Co-author DOI 10.1097/pai.0000000000000764↗
  10. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  11. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  12. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma Co-author DOI 10.1101/663583↗
  13. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-19-0370↗
  14. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  15. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  16. Genetics and Biology of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.hoc.2015.04.003↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aram F. Hezel · 11 shared papers, 2015–2024 · strength 1.00
  2. Brian Matthew Wolpin · 10 shared papers, 2017–2023 · strength 0.76
  3. David C. Linehan · 7 shared papers, 2017–2023 · strength 0.69
  4. Albert C. Koong · 9 shared papers, 2017–2023 · strength 0.69
  5. Daniel Tandel Chang · 9 shared papers, 2017–2023 · strength 0.69
  6. Jonathan Andrew Nowak · 9 shared papers, 2017–2023 · strength 0.69
  7. Vicente Morales‐Oyarvide · 8 shared papers, 2017–2023 · strength 0.61
  8. Chen Yuan · 7 shared papers, 2017–2023 · strength 0.55
  9. Thomas E. Clancy · 7 shared papers, 2017–2023 · strength 0.55
  10. Douglas Adam Rubinson · 7 shared papers, 2017–2023 · strength 0.55
  11. Margaret M. Kozak · 7 shared papers, 2017–2023 · strength 0.55
  12. Andressa Dias Costa · 6 shared papers, 2019–2023 · strength 0.53
  13. Andrew J. Aguirre · 6 shared papers, 2018–2023 · strength 0.50
  14. Charles S. Fuchs · 7 shared papers, 2017–2021 · strength 0.47
  15. Sara A. Väyrynen · 5 shared papers, 2019–2023 · strength 0.45
  16. Diana Agostini‐Vulaj · 3 shared papers, 2020–2024 · strength 0.41
  17. Ana Babić · 6 shared papers, 2017–2020 · strength 0.39
  18. Kimberly J. Perez · 4 shared papers, 2019–2023 · strength 0.36
  19. Kimmie Ng · 5 shared papers, 2017–2022 · strength 0.35
  20. Eric J. Roeland · 1 shared paper, 2022 · strength 0.33
  21. Jiping Wang · 3 shared papers, 2021–2023 · strength 0.31
  22. Hannah L. Williams · 3 shared papers, 2021–2023 · strength 0.31
  23. Wenjia Wang · 2 shared papers, 2021–2024 · strength 0.30
  24. Philip Bonomi · 1 shared paper, 2024 · strength 0.23
  25. Natalia I. Khalaf · 4 shared papers, 2017–2019 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.